ArticleWideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques2024
Early results of laparoscopic single‑anastomosis duodeno‑ileal bypass with sleeve gastrectomy: a case series from a single Polish bariatric center.
Article in Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Type 2 diabetes mellitus remission 10 years after metabolic and bariatric surgery: a multicenter retrospective study in Poland (BARI‑10‑POL).Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2026Article
- Metabolic and bariatric surgery reduces aging biomarkers in patients with obesity, independently of achieving optimal total weight loss.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe obesity epidemic has led to an increased prevalence of related conditions, such as type 2 diabetes (T2D) and hypertension. While laparoscopic sleeve gastrectomy is the most common metabolic bariatric surgery, up to 50% of patients may require revisional procedures due to weight regain or comorbidity recurrence. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) is emerging as an effective treatment option with promising short-term outcomes.
aimThis study aimed to present the outcomes of patients who underwent SADI-S or revisional SADI. MATERIALS AND
methodsThis retrospective, single-center cohort study included 12 patients who underwent SADI-S or SADI between February 2023 and March 2024. The patients were assessed for percentage of total weight loss (%TWL), remission of T2D and hypertension, length of hospital stay, operative time, and complications. All outcomes were reported according to the American Society for Metabolic and Bariatric Surgery standards.
resultsA total of 9 patients underwent primary SADI-S and 3 underwent revisional SADI. The mean (SD) %TWL was 27.9% (4.3%) at 6 months and 31.1% (5.9%) at 12 months after SADI and 21.2% (15.2%) and 14% (7.5%), respectively, after SADI-S. The mean (SD) preoperative body mass index was 42 (5.5) kg/m2 in the primary SADI-S group and 42.4 (9.3) kg/m2 in the revisional SADI group, and the mean (SD) follow-up was 10.1 (3.4) months. Full remission of T2D and hypertension was achieved in all patients within 6 months of surgery. There were no major complications, except for 1 case of intraoperative conversion to one-anastomosis gastric bypass.
conclusionsSADI-S is associated with significant weight loss and comorbidity resolution with a low complication rate, though larger studies are needed for further validation of these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.